Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 5, 2025
BALA CYNWYD, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2025 operating and financial results.
Read more at globenewswire.com
